Immunodeficiency Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Immunodeficiency stocks.

Immunodeficiency Stocks Recent News

Date Stock Title
May 17 BMY AbbVie Is 'Successfully Positioned To Absorb Humira Biosimilar Erosion': Analyst
May 17 BMY The Zacks Analyst Blog Highlights Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers
May 17 BMY Erasca restructures; Novartis moves to complete MorphoSys deal
May 17 BMY BMS reports four-year data from psoriasis treatment extension trial
May 16 BMY Walmart Earnings & the State of the Consumer
May 16 BMY Biotech Stock Roundup: NVAX, FULC Up on Deals With SNY, Updates From MRNA, BMY
May 16 BMY New Four-Year Sotyktu (deucravacitinib) Data Demonstrate Durable Response Rates and Consistent Safety in Moderate-to-Severe Plaque Psoriasis
May 16 BMY Bristol Myers (BMY) Gets FDA Nod for Breyanzi Label Expansion
May 16 BMY FDA approves Bristol Myers Squibb’s Breyanzi for follicular lymphoma
May 16 BMY Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma
May 15 BMY Bristol-Myers Squibb Company (BMY) Bank of America Global Healthcare Conference 2024 Transcript
May 15 BMY Tudor Investment's top buys and sells in Q1
May 15 BMY Bristol Myers' Breyanzi gains additional indication for follicular lymphoma
May 15 BMY UPDATE 3-US FDA approves expanded use of Bristol Myers' cancer cell therapy
May 15 GILD Gilead Sciences, Inc. (GILD) RBC Capital Markets Global Healthcare Conference (Transcript)
May 15 INO Inovio Pharmaceuticals, Inc. (INO) Presents at 2024 RBC Capital Markets Global Healthcare Conference (Transcript)
May 15 AEMD Aethlon Medical announces pricing of $4.7 million public offering
May 15 AEMD Aethlon Medical Announces Pricing of $4.7 Million Public Offering
May 15 AEMD Why Arcutis Biotherapeutics Shares Are Trading Higher By 29%; Here Are 20 Stocks Moving Premarket
May 15 NNVC NanoViricides GAAP EPS of -$0.16
Immunodeficiency

Immunodeficiency, also known as immunocompromisation, is a state in which the immune system's ability to fight infectious diseases and cancer is compromised or entirely absent. Most cases are acquired ("secondary") due to extrinsic factors that affect the patient's immune system. Examples of these extrinsic factors include HIV infection and environmental factors, such as nutrition.
Immunocompromisation may also be due to genetic diseases/flaws. An example here is SCID.
In clinical settings, immunosuppression by some drugs, such as steroids, can either be an adverse effect or the intended purpose of the treatment. Examples of such use is in organ transplant surgery as an anti-rejection measure and in patients suffering from an overactive immune system, as in autoimmune diseases. Some people are born with intrinsic defects in their immune system, or primary immunodeficiency.A person who has an immunodeficiency of any kind is said to be immunocompromised. An immunocompromised individual may particularly be vulnerable to opportunistic infections, in addition to normal infections that could affect anyone. It also decreases cancer immunosurveillance, in which the immune system scans the body's cells and kills neoplastic ones.

Browse All Tags